Gut Cancer Gene GLIS3 Found to Fuel Tumors Through a Vitamin B6 Enzyme and Autophagy

Gastric cancer remains one of the most formidable malignancies worldwide, a disease that continues to drive cancer incidence and mortality upward despite decades of progress in surgery, chemotherapy, and immunotherapy. Now, a team of researchers in China has uncovered a previously hidden molecular circuit that helps gastric cancer cells proliferate, migrate, and invade surrounding tissue. The study, published in the journal Medical Oncology, centers on a transcription factor called GLIS family zinc finger 3, or GLIS3, and reveals how this gene acts as a master switch that revs up a cellular recycling process known as autophagy, giving tumor cells a survival advantage that translates into worse outcomes for patients.

The research, led by Yuejin Li and Yiming Ouyang of the Department of General Surgery at the First People’s Hospital of Yunnan Province, together with senior authors Kunmei Gong and Linhai Li, began with a straightforward but critical clinical observation. By analyzing tumor samples and patient data, the team found that GLIS3 expression was significantly elevated in gastric cancer patients compared with healthy tissue. More strikingly, high levels of the gene correlated with shortened survival, marking GLIS3 as a potential prognostic indicator. This finding builds on earlier work suggesting that GLIS3, a zinc finger transcription factor best known for its roles in thyroid development, pancreatic beta cell function, and kidney physiology, can behave as an oncogenic driver in several cancers, including glioma, triple-negative breast cancer, and gastric adenocarcinoma.

To understand what GLIS3 actually does inside gastric cancer cells, the researchers turned to MKN-45 cells, a well-established gastric cancer cell line, and used molecular tools to silence the gene. The results were dramatic. When GLIS3 was knocked down, the cells lost much of their malignant character: proliferation measured by CCK-8 assays dropped, colony formation in soft culture declined, and the cells’ ability to migrate through Transwell membranes and invade through extracellular matrix coatings was markedly impaired. The team then confirmed these findings in living organisms by injecting MKN-45 cells subcutaneously into nude mice to establish a tumor-bearing model. Tumors with suppressed GLIS3 grew significantly more slowly than controls, providing in vivo evidence that the gene is not merely a passenger mutation but an active promoter of tumor growth.

The next question was how GLIS3 exerts these effects. The researchers suspected autophagy, the conserved cellular process in which cells digest their own damaged components and recycle nutrients to survive stress. Autophagy has a complicated relationship with cancer: in early tumor formation it can suppress malignancy, but in established tumors it often acts as a lifeline, helping cancer cells endure hypoxia, nutrient deprivation, and chemotherapy. Using immunofluorescence and monodansylcadaverine (MDC) staining, both standard techniques for visualizing autophagic structures, the team showed that silencing GLIS3 suppressed key autophagy-related indicators in the gastric cancer cells. In other words, part of GLIS3’s tumor-promoting power comes from its ability to keep the autophagy machinery running at high speed.

The crucial mechanistic breakthrough came when the investigators identified the downstream target of GLIS3. Using chromatin immunoprecipitation, or ChIP, a technique that detects which proteins bind to specific DNA regions inside cells, the researchers demonstrated that GLIS3 physically attaches to the promoter region of a gene called PNPO, which encodes pyridoxine 5′-phosphate oxidase, the enzyme responsible for producing the active form of vitamin B6, pyridoxal phosphate. The ChIP experiments confirmed direct binding, and follow-up analyses showed that GLIS3 promotes PNPO transcription. This is a significant discovery because PNPO has recently emerged as an unexpected player in tumor biology. Prior studies have linked the enzyme to breast invasive ductal carcinoma development, to lysosomal activity in macrophages under prolonged hypoxia, and to ovarian cancer, where targeting PNPO suppressed tumor growth by inhibiting autophagic flux and even reversed paclitaxel resistance.

To test whether PNPO is truly the mediator of GLIS3’s effects, the researchers performed a rescue experiment, one of the most rigorous designs in molecular cancer biology. They knocked down GLIS3 in MKN-45 cells and then forced the cells to overexpress PNPO. The result: the malignant behaviors returned. Cell viability, proliferation, migration, invasion, and autophagy all rebounded when PNPO was restored, even in the absence of GLIS3. This demonstrated that PNPO sits downstream of GLIS3 in the regulatory hierarchy and is sufficient to drive the aggressive phenotype on its own. The pathway, in essence, runs from GLIS3 in the nucleus, through the PNPO promoter, to elevated PNPO expression, and finally to enhanced autophagic activity that sustains tumor cell fitness.

The final piece of the puzzle came from pharmacological intervention. When the researchers added 3-methyladenine, commonly abbreviated as 3-MA, a widely used inhibitor of autophagy that blocks the class III phosphatidylinositol 3-kinase required for autophagosome formation, the tumor-promoting effects of PNPO overexpression were significantly weakened. This experiment closes the logical loop: if PNPO drives malignancy through autophagy, then blocking autophagy should blunt PNPO’s effects, and that is precisely what the team observed. The finding suggests that the GLIS3-PNPO axis promotes gastric cancer specifically by activating autophagic flux, and that disrupting this process could undermine the malignant behavior of tumor cells even when upstream drivers remain active.

The clinical implications of this work are considerable. Gastric cancer is frequently diagnosed at advanced stages, and five-year survival rates remain poor in many parts of the world, particularly where screening programs are limited. A molecular signature based on GLIS3 and PNPO expression could help clinicians identify patients at higher risk of aggressive disease and earlier mortality. More ambitiously, the pathway offers potential therapeutic targets. If GLIS3’s oncogenic activity depends on its transcriptional control of PNPO, then strategies to interfere with that binding, or to inhibit PNPO enzymatic activity directly, could starve gastric tumors of the autophagy-dependent survival advantage they rely upon. The ovarian cancer data cited by the authors, showing that PNPO targeting can reverse chemotherapy resistance, hint that this approach might also sensitize gastric tumors to existing treatments.

Cautious interpretation is still warranted. The study relies primarily on a single gastric cancer cell line, MKN-45, and on subcutaneous xenograft models in immunodeficient mice, which do not fully recapitulate the complex immune microenvironment of human gastric tumors. Whether the GLIS3-PNPO-autophagy axis operates identically across the molecular subtypes of gastric cancer, from intestinal-type adenocarcinomas to diffuse signet ring cell carcinomas, remains to be established. Clinical translation will also require the development of specific inhibitors capable of targeting PNPO or disrupting GLIS3-DNA interactions in patients, tools that do not yet exist in the clinic. Nonetheless, the study adds an important link to a growing chain of evidence that GLIS3 family transcription factors, previously studied in the context of development and metabolic disease, are versatile oncogenic regulators that hijack fundamental cellular processes. By revealing how a vitamin B6-metabolizing enzyme connects a transcription factor to the autophagy machinery, the researchers have opened a new avenue for understanding, and potentially attacking, one of the world’s deadliest cancers.

Subject of Research: The role of GLIS3 transcriptional regulation of PNPO in autophagy-mediated malignant behavior of gastric cancer cells

Article Title: GLIS3 promotes the malignant biological behavior of gastric cancer cells by transcriptionally regulating PNPO to influence autophagy

Article References: Li, Y., Ouyang, Y., Zhu, Y., Hou, D., Li, X., Guo, X., Sheng, P., Wu, H., Liao, Y., Gong, K., & Li, L. (2026). GLIS3 promotes the malignant biological behavior of gastric cancer cells by transcriptionally regulating PNPO to influence autophagy. Medical Oncology, 43(11), Article 319. https://doi.org/10.1007/s12032-026-03433-0

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03433-0

Keywords: gastric cancer, GLIS3, PNPO, autophagy, transcription factor, tumor biology, MKN-45, vitamin B6 metabolism, 3-methyladenine, cancer prognosis, xenograft model, Medical Oncology